292 related articles for article (PubMed ID: 21402611)
1. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
Paiva B; Martinez-Lopez J; Vidriales MB; Mateos MV; Montalban MA; Fernandez-Redondo E; Alonso L; Oriol A; Teruel AI; de Paz R; Laraña JG; Bengoechea E; Martin A; Mediavilla JD; Palomera L; de Arriba F; Bladé J; Orfao A; Lahuerta JJ; San Miguel JF
J Clin Oncol; 2011 Apr; 29(12):1627-33. PubMed ID: 21402611
[TBL] [Abstract][Full Text] [Related]
2. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
3. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
6. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
8. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
Durie BG; Jacobson J; Barlogie B; Crowley J
J Clin Oncol; 2004 May; 22(10):1857-63. PubMed ID: 15111617
[TBL] [Abstract][Full Text] [Related]
9. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
[TBL] [Abstract][Full Text] [Related]
10. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
11. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
14. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
Honma R; Fukase S; Suzuki M; Omoto E
Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
16. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.
Krebs MG; Sloane R; Priest L; Lancashire L; Hou JM; Greystoke A; Ward TH; Ferraldeschi R; Hughes A; Clack G; Ranson M; Dive C; Blackhall FH
J Clin Oncol; 2011 Apr; 29(12):1556-63. PubMed ID: 21422424
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
20. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
